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Abstract
Aim The aim of this study is to compare the
24-hour efficacy of dorzolamide/timolol-fixed
combination (DTFC) and brimonidine/
timolol-fixed combination (BTFC) in primary
open-angle glaucoma (POAG).
Methods One eye each of 77 POAG
patients was included in this prospective,
observer-masked, crossover comparison.
Following a 2-month timolol run-in period,
patients had three intraocular pressure (IOP)
measurements at 1000, 1200 and 1400 h while
on timolol treatment. Patients showing at least
a 20% IOP reduction on timolol were
randomised to 3 months of therapy with DTFC
or BTFC, and then were crossed over to the
opposite therapy.
Results Sixty POAG patients completed the
study. The mean 24-hour IOP was significantly
reduced with both the fixed combinations
compared with the timolol-treated diurnal IOP
(Po0.001). When the two fixed combinations
were compared directly, DTFC demonstrated a
lower mean 24-hour IOP level as compared
with BTFC (mean difference: 0.7mmHg, 95%
confidence interval (CI): (1.0, 0.3), Po0.001).
At two individual time points, DTFC
significantly reduced IOP more than BTFC: at
1800h (1.0mmHg, 95% CI (1.6,0.5),
P¼ 0.001) and at 0200 (0.9mmHg, 95% CI:
(1.4,0.5), P¼ 0.001). No significant
difference existed for the other time points.
Conclusion Both the fixed combinations
significantly reduce 24-hour IOP in POAG.
DTFC provided significantly better 24-hour
efficacy.
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Introduction
Orally administered fixed-dose combinations
have been shown to improve adherence to
chronic medical therapy.1–4 It is known that
almost half of the patients with chronic,
asymptomatic diseases do not take their
medications as prescribed.5–8 In medicine,
a recent meta-analysis showed that non-
adherence to medical therapy is reduced by
24–26% with fixed-dose combination regimens
compared with unfixed concomitant therapies.3
Fixed combinations of glaucoma medications, in
most cases, provide similar intraocular pressure
(IOP) reduction to that observed with
simultaneous administration of their individual
components,1,9 simplify adjunctive medication
regimens,10,11 reduce the incidence of adverse
events,12,13 and may improve adherence and
long-term tolerability.1,12,14
The dorzolamide/timolol-fixed combination
(DTFC, Cosopt) and the brimonidine/timolol-fixed
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combination (BTFC, Combigan) are commonly-
prescribed fixed combinations for the treatment of
glaucoma that have been approved in several countries
worldwide.12,13 Separate diurnal IOP comparisons
between fixed and unfixed therapy with DTFC15 and
BTFC16 have reported similar efficacy. More recently, a
study in which IOP was measured over 24 h17 compared,
for the first time, BTFC with the concomitant
administration of its individual components and
reported similar efficacy between the two regimens.
Nevertheless, the mean IOP reduction over 24 h (22%)
observed with BTFC was less than anticipated.17
Although this range of pressure reduction is consistent
with the evidence obtained from the regulatory trials for
BTFC,18,19 the extent of the 24-h IOP reduction is less than
that observed with DTFC.20 Specifically, with DTFC,
reported daytime IOP reduction ranges from 27 to 33%21–24
and the 24-h IOP reduction ranges between 26 and
28%25–27 in published studies.
At present, there are few data from randomised clinical
studies directly comparing these two fixed combinations,
and the data that have been reported suggest similar
daytime efficacy.28,29 A more detailed comparison of the
efficacy of the two combinations can be made by
recording IOP throughout a 24-h period.30
The purpose of the present study is to compare the
difference in IOP-lowering efficacy when measured over
24 h, between these two fixed combinations in patients
with primary open-angle glaucoma (POAG).
Materials and methods
Informed consent was obtained from all participants
before they entered this observer-masked, crossover
study.
Patient eligibility
Consecutive adults with newly diagnosed, early-to-
moderate POAG (defined as glaucomatous disc damage
with vertical disc cupping not exceeding 0.8. and
reproducible glaucomatous visual field loss less than
12.0 dB in the study eye with Humphrey 24-2 automated
perimetry) were recruited in three academic participating
centres: the Glaucoma Unit of the 1st University
Department of Ophthalmology, AHEPA Hospital,
Thessaloniki, Greece; the Center for the Study of
Glaucoma, University of Brescia, Brescia, Italy; and
Ophthalmic Consultant Centres, University of Toronto,
Mississauga, ON, Canada. All study candidates had to
exhibit a typical disc or visual field damage, a mean
untreated IOP greater than 25 mm Hg at baseline (two
IOP measurements performed at 1000±1 h), and central
corneal thickness between 500–600mm.
All newly diagnosed, previously untreated POAG
patients who agreed to participate and met the inclusion
and exclusion criteria in the three study centres were
enrolled. Inclusion criteria were age between 39 and
85 years; best-corrected distance Snellen visual acuity
greater than 0.1 in the study eye; early-to-moderate
POAG (defined as patients who exhibit glaucomatous
disc damage with disc cupping not exceeding 0.8, and
reproducible glaucomatous visual field loss with a mean
deviation better than 12.0 dB in the study eye with
Humphrey 24-2 SITA standard automated perimetry);
patient could safely undergo wash out; open anterior
chamber angles; untreated baseline IOP greater than
25 mm Hg, and lower than 40 mm Hg at 1000 (±1 h).
Exclusion criteria
Exclusion criteria were evidence of concurrent
conjunctivitis, keratitis, or uveitis in either eye; history
of ocular herpes simplex, or macular oedema; history of
inadequate adherence; allergic hypersensitivity,
intolerance, or contraindication to either b-blockers,
brimonidine, dorzolamide, or benzalconium chloride;
intraocular conventional or laser surgery in the study
eye; child-bearing potential or lactation; previous history
of ocular trauma; use of corticosteroids (within 2 months
before the enrolment), severe dry eyes; and use of contact
lenses. The demographics of the study patients are
shown in Table 1.
Procedures
All eligible patients underwent first a timolol 0.5% run-in
period for at least 8 weeks before the randomisation to
either DTFC or BTFC. Enrolled patients were treated for
at least 8 weeks with timolol 0.5% given twice daily (0800
and 2000 h). After this run-in period, they underwent a
timolol-treated daytime IOP assessment with three
separate IOP measurements performed at 1000, 1200 and
1400 h. Only patients with a mean daytime IOP (average
Table 1 Baseline characteristics (n¼ 60 completed patients)
Characteristic
Male, n (%) 27 (45.0)
Female, n (%) 33 (55.0)
Mean age (years)±SD 65.3±11.9
Range 31.0, 81.0
Mean morning baseline IOP pressure (mm Hg)±SD 27.9±2.7
Mean Snellen best-corrected visual acuity±SD 0.9±0.2
Mean vertical cup/disc ratio±SD 0.6±0.2
Mean visual field loss mean deviation (dB)±SD 4.5±3.6
Abbreviation: IOP, intraocular pressure.
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of these three measurements) on timolol monotherapy
greater than 18 mm Hg, and a mean reduction of morning
IOP (1000±1 h), at least 20%, were randomised for
period 1 to either 3 months of chronic therapy with DTFC
given twice daily (0800 and 2000 h), or to 3 months with
BTFC given twice daily (0800 and 2000 h). At the end of
period 1, all study patients underwent a treated 24-h IOP
assessment. Patients then were switched for period 2 to
the opposite therapy (with either DTFC or BTFC), and at
the end of this period, they also underwent a 24-h IOP
evaluation.
During the eligibility visit, subjects’ ophthalmic and
systemic histories were recorded. Slit lamp
biomicroscopy, dilated fundoscopy, and automated
threshold perimetry were performed, and best-corrected
visual acuity and IOP were measured. Enrolled subjects
were admitted to hospital and underwent 24-h IOP
monitoring at 1000, 1400 1800, 2200, 0200, and 0600 h
(±1 h) while sitting upright. Two pressure readings were
taken for every time point of the 24-h curve.
The subsequent study phases were observer-masked.
Study patients were randomly assigned to receive BTFC
drops (Combigan, Allergan Inc., Irvine, CA, USA) twice
daily (0800 and 2000 h), or DTFC drops (Cosopt, Merck,
Whitehouse Station, NJ, USA) administered twice daily
(0800 and 2000 h) for Period 1. At the end of Period 1, all
patients were switched to the opposite dosing regimen
for Period 2. Patients were instructed regarding correct
medication instillation and compliance. A safety visit
was carried out 2 weeks after the two treatment periods.
At the end of each treatment period, a 24-h IOP curve
and a detailed clinical examination were performed. The
IOP was always measured by the same investigators who
were unaware of the treatment regime, using the same
calibrated Goldmann tonometer.
Statistics
The primary efficacy endpoint for this crossover study
was the mean 24-h IOP (the mean pressure for the six
time points measured). The individual time points, peak,
minimum, and 24-h IOP fluctuation were evaluated as
secondary endpoints. A generalised estimating equation
was used for the crossover repeated measures design to
adjust for site differences and baseline, or timolol run-in
IOP. A 95% confidence interval (CI) was constructed for
the adjusted difference in means. An intention-to-treat
approach was adopted, and the subjects were analysed
according to their randomised group. The mean IOP of
all other patients in the corresponding treatment group
was used to impute the missing data for those subjects
lost to follow-up. In addition, the per-protocol analysis
was performed.
The modified Bonferroni-adjusted P-values were
reported to correct the analyses for multiple comparisons
with individual time points.31 All other reported
P-values were two-tailed, with Po0.05 considered as
significant. This 24-h study had at least 85% power to
identify a 1.0 mm Hg difference between individual time
points and between mean 24-h pressures assuming an SD
of 2.5 mm Hg between treatments.
Adverse events were evaluated by McNemar’s test for
all patients that completed this study.32 Analyses were
conducted using SPSS 15.0 (SPSS Inc., Chicago, IL, USA).
Results
Patients
Patient characteristics of those included in this study are
shown in Table 1. Sixty patients completed the study out
of 77 enrolled. The flow diagram of study participants is
presented in Figure 1. Four patients withdrew after
randomisation and declined further participation due to
difficulties in undergoing repeated IOP monitoring; none
of those discontinuations were due to adverse events.
Out of the 70 study patients who underwent the timolol
diurnal curve, 5 did not meet the study IOP inclusion
criterion, and were excluded. From the 65 patients who
were randomised to the fixed combination therapies,
5 were withdrawn due to adverse events: 2 in the DTFC
period and 3 in the BTFC period. Two patients were
discontinued due to intolerance to DTFC; one patient
was discontinued from the BTFC group due to systemic
hypotension, and two due to intolerance.
Intraocular pressure
The mean 24-h IOP, and the IOP reductions from
untreated baseline and from the mean timolol-treated
diurnal IOP are shown in Table 2 and Figure 2. The mean
24-h IOP was significantly reduced from the timolol
diurnal IOP baseline for both the fixed combinations
(2.9 mm Hg (13.9%) for DTFC and 2.2 mm Hg (10.5%)
for BTFC; Po0.001). When the two fixed combination
treatments were compared directly, the DTFC
demonstrated a lower absolute IOP level for the
24-h curve, compared with the BTFC (mean difference:
0.7 mm Hg, 95% CI: 1.0, 0.3).
In Table 3, the absolute IOP of the individual time
points, peak, minimum, and 24-h fluctuation (or range)
together with their mean differences are being compared
between the two fixed combination treatment groups.
At two individual time points (1800 and 0200 h), DTFC
reduced IOP significantly more than BTFC (P¼ 0.001 for
both comparisons). No statistical differences existed for
the other four time points: 0600, 1000, 1400, and 2200 h
(P40.05), and for the 24-h fluctuation (P¼ 0.34).
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The peak and minimum 24-h IOP were, however,
significantly lower with DTFC compared with BTFC
(P¼ 0.003 and P¼ 0.033, respectively). These results were
similar when the per-protocol analysis was performed.
Adverse events
No serious adverse event concerns were identified
during this study. Patients treated with DTFC
experienced bitter taste (18.3%) and stinging (16.7%)
more often than when treated with BTFC (P¼ 0.001 and
P¼ 0.012, respectively). Conversely, more patients
experienced conjuctival hyperaemia with BTFC
compared with DTFC (16.7 vs 5.0%, P¼ 0.039). There
were no significant differences in the other adverse
events between the two fixed combination treatment
groups (see Table 4).
Discussion
Fixed combination therapy in glaucoma has gained
popularity in recent years, presumably because of the
Table 2 Comparison of IOP levels (mm Hg)
Untreated (95% CI) Diurnal timolol (95% CI) 24-h DTFC (95% CI) 24-h BTFC (95% CI)
Mean 27.9 (27.2, 28.7)a 20.9 (20.4, 21.4)b 18.0 (17.5, 18.6)c 18.7 (18.1, 19.4)c
Mean adjusted difference
from untreated
F 6.9 (7.4, 6.4)b
Po0.001
9.9 (10.6, 9.2)c
Po0.001
9.2 (9.9, 8.5)c
Po0.001
Mean adjusted difference
from diurnal timolol
F F 2.9 (3.4, 2.5)c
Po0.001
2.2 (2.8, 1.7)c
Po0.001
Mean 24-h adjusted difference F F 0.7 (1.0, 0.3)c
Po0.001
F
Abbreviations: BTFC, brimonidine/timolol-fixed combination; CI, confidence interval; DTFC, dorzolamide/timolol-fixed combination.
aAdjusted for site.
bAdjusted for site and untreated IOP.
cAdjusted for site and timolol run-in period.
Patients screened (n=77)
Excluded (n=7)
Not meeting
inclusion criteria (n=3)
Refused to participate
(n=4)
Timolol run-in period
(n=70) 
DTFC (n=32)
Withdrawals (n=2)
BTFC (n=33)
Withdrawals (n=3)Treatment period 1 
BTFC (n=30) DTFC (n=30)Treatment period 2
Total completed trial (n=60)
Randomized (n=65)
Excluded (n=5)
IOP < 18 mmHg (n=3)
IOP reduction < 20%
(n=2)
Figure 1 Flow diagram of patients enrolled in study.
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perceived benefits of greater patient convenience and
adherence.1–3 At present, DTFC and BTFC are the only
fixed combinations approved by the Food and Drug
Administration in the United States.12 To date, regulatory
approval for fixed combination therapy for glaucoma is
based on efficacy and safety comparisons between fixed
combinations and the individual components, or the
concomitant use of both constituents.1,9,12 This approach,
solely based on pharmacologic efficacy, is not ideal, as it
does not take into account other important clinical
benefits such as enhanced adherence, improved
convenience, and reduced cost to patients.1 Moreover,
there is no uniformity among regulatory trials, and it is
generally difficult to compare the efficacy between fixed
combinations in the same therapeutic category.
To the best of our knowledge, this is the first study
comparing the 24-h efficacy of these two fixed
combinations. Although both BTFC and DTFC dose
timolol 0.5% twice daily, the pharmacologic difference in
the second component of these fixed combinations
(brimonidine vs dorzolamide) may account for the
relative differences in 24-h IOP efficacy observed in the
present study. Brimonidine is a relatively short-acting
medication, and when instilled twice daily, may have a
relatively weak IOP-lowering effect at trough and during
the night.33–35 In the study by Orzalesi et al,34
brimonidine monotherapy dosed twice daily did not
significantly reduce IOP from untreated baseline at 1800
and 0300 time points. These time points closely mirror
the two time points in our study (1800 and 0200) in which
DTFC provided significantly better IOP control than
BTFC. Further, a recent 24-h study by Liu et al36
demonstrated the absence of measurable nocturnal
efficacy for brimonidine even with three times per day
Table 3 Absolute IOP levels (mm Hg)
Time points (h) DTFC Mean (95% CI) BTFC Mean (95% CI) Mean adjusted difference (95% CI)a P-value
0600 18.4 (17.7, 19.1) 18.7 (18.0, 19.5) 0.3 (0.9, 0.2) 0.203b
1000 17.7 (17.0, 18.3) 18.2 (17.5, 18.9) 0.5 (1.1 0.1) 0.070b
1400 17.5 (16.9, 18.2) 18.1 (17.4, 18.7) 0.5 (1.1, 0.1) 0.057b
1800 17.9 (17.1, 18.6) 18.9 (18.1, 19.7) 1.0 (1.6, 0.5) 0.001b
2200 17.2 (16.6, 17.9) 17.8 (17.1, 18.5) 0.6 (1.1, 0.1) 0.068b
0200 18.2 (17.6, 18.8) 19.1 (18.4, 19.8) 0.9 (1.4, 0.5) 0.001b
Mean 24 18.0 (17.5, 18.6) 18.7 (18.1, 19.4) 0.7 (1.0, 0.3) o0.001
Maximum 20.0 (19.3, 20.6) 20.7 (20.0, 21.4) 0.7 (1.2, 0.3) 0.002
Minimum 15.8 (15.3, 16.4) 16.3 (15.7, 17.0) 0.5 (0.9, 0.1) 0.033
Fluctuation 4.1 (3.6, 4.6) 4.3 (3.8, 4.9) 0.2 (0.7, 0.2) 0.340
Abbreviations: BTFC, brimonidine/timolol-fixed combination; CI, confidence interval; DTFC, dorzolamide/timolol-fixed combination.
aAdjusted for site and timolol run-in period.
bModified Bonferroni adjusted P-values.
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Figure 2 The figure shows the mean IOP±95% CI at each
individual time point and for the 24-h pressure for DTFC (solid
black line) and BTFC (gray line) treatment groups.
Table 4 Adverse events recorded in the study (n¼ 60
completed patients)
Adverse eventa DTFC, n (%) BTFC, n (%) P-value
Bitter taste 11 (18.3) 0 (0) 0.001
Stinging 10 (16.7) 1 (1.7) 0.012
Conjunctival hyperaemia 3 (5.0) 10 (16.7) 0.039
Itchiness 1 (1.7) 7 (11.7) 0.070
Burning 4 (6.7) 0 (0) 0.125
Systemic hypotension 0 (0) 4 (6.7) 0.125
Dry mouth 0 (0) 4 (6.7) 0.125
Foreign body sensation 0 (0) 3 (5.0) 0.250
Dry eye sensation 1 (1.7) 3 (5.0) 0.625
Fatigue 1 (1.7) 3 (5.0) 0.625
Watering 1 (1.7) 2 (3.3) 1.000
SPK 1 (1.7) 0 (0) 1.000
Ocular discharge 0 (0) 1 (1.7) 1.000
Eyelid swelling 1 (1.7) 0 (0) 1.000
Headache 0 (0) 1 (1.7) 1.000
Dizziness 0 (0) 1 (1.7) 1.000
Drowsiness 0 (0) 1 (1.7) 1.000
Abbreviations: BTFC, brimonidine/timolol-fixed combination; CI, confi-
dence interval; DTFC: dorzolamide/timolol-fixed combination.
aSome patients experienced multiple adverse events.
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dosing. It is worthwhile noting that in that 24-h study,
there was no statistically significant change in IOP under
brimonidine therapy compared with baseline untreated
IOP during the nocturnal period, but there was a
significant lowering of IOP during the daytime diurnal
period in both supine and sitting positions.36 In contrast,
dorzolamide monotherapy has demonstrated significant
nocturnal IOP-lowering efficacy.20,35,37 In two separate 24-h
studies,35,37 the nocturnal efficacy of dorzolamide was
equivalent to that of latanoprost. A recent meta-analysis of
24-h studies demonstrated that mean reduction of night
time points (1800, 2200, and 0200 h) was statistically lower
than that of day time points for timolol and brimonidine,
but not for dorzolamide.20 This meta analysis is again
consistent with the 1800 and 0200 h time points in this
study, when BTFC was statistically inferior to DTFC.
Our study enrolled newly diagnosed, previously
untreated POAG patients with a relatively high-
untreated IOP to ensure uniformity of the study cohort
and to enhance the power of study, to detect any
differences between the two medications if present.
The study design employed three relatively stringent
inclusion criteria of (1) baseline untreated IOP425 mm Hg,
(2) initial response to timolol 0.5 420%, and (3) timolol-
treated IOP 418 mm Hg. These strict inclusion criteria
ensured that both timolol non-responders and patients
who had already reached a reasonable target IOP with
timolol monotherapy were both excluded from the study.
Timolol dosed twice daily reduced untreated IOP in our
cohort by 25.1%. The efficacy comparison between
timolol run-in and the treatment periods with the two
medications under investigation indicate that both fixed
combinations significantly reduced mean 24-h IOP
compared with timolol monotherapy.
The comparison between the two fixed combinations
in this study demonstrated that DTFC was superior to
BTFC at two individual time points (1800 and 0200 h), as
well as the mean, maximum, and minimum 24-h
pressure. However, mean 24-h IOP fluctuation was
similar between DTFC and BTFC. Our results
demonstrated a significant difference between DTFC and
BTFC (0.7 mm Hg over a 24-h period), unlike the
findings of the two previous daytime studies in which no
significant difference was detected.28,29 Significant
differences in this study design compared with those
previous studies include: (1) crossover design vs parallel
arm, (2) inclusion of only POAG patients, (3) a higher
baseline untreated IOP, (4) exclusion of patients
adequately responding to timolol monotherapy, and (5)
a more complete 24-h IOP evaluation of the two fixed
combinations. All of the above factors contributed to
a greater power in this study to detect small but
significant differences between the two fixed
combinations.
Although most previously published daytime
studies28,29 have demonstrated similar IOP-lowering
efficacy for BTFC over DTFC, a recent 3-month
parallel-arm study by Nixon et al38 reported a greater IOP
reduction with BTFC monotherapy (7.7 mm Hg)
compared with DTFC monotherapy (6.7 mm Hg). The
study by Nixon et al38 pooled data from two separate
trials: a single site pilot study with 40 patients, and a
multi-centre trial with 140 patients. Out of the total of 180
patients, 101 were treated with BTFC or DTFC as
monotherapy (30 from the pilot study, 71 from the
multi-centre trial), whereas 79 patients were treated
as an adjunct to prostaglandin therapy.38 The
methodology of that study was critically differed from
the protocol utilised in the present study in several ways.
First, the Nixon study38 measured IOP at a single time
point (1000) at 2 h post dose. This time point would be
near the peak efficacy for brimonidine, which tends to
have a rapid onset of action.12,18–20,39 The current study
measures IOP every 4 h over a 24-h time period.
Although no differences between the two fixed
combinations were observed at the two corresponding
time points 2 h post-dose (1000 and 2200 h), we did
observe significant differences in favour of DTFC at
1800 h (near the trough efficacy of brimonidine) and at
0200 (during the overnight period where brimonidine
has previously been shown to have a weaker effect).
The different findings when comparing a single time
point study to a 24-h study highlight again the
importance of measuring IOP over 24 h to properly
assess the efficacy of glaucoma medications.30 Second,
the Nixon study.38 was a parallel-arm design, whereas
the current study had a crossover design. Parallel arm
studies tend to require much larger patient numbers to
achieve the same statistical power compared with
crossover studies. The Nixon study showed a weakly
significant superiority (P¼ 0.04) in favour of BTFC at a
single time point, whereas the current study showed a
stronger statistical significance in favour of DTFC
(Po0.001) over 24 h. Third, the Nixon paper required the
pooling of data from two separate trials to achieve a
weak statistical signficance, whereas the current 24-h
study is reporting results from a single trial. Finally, all of
the patients in this study were naive to treatment before
the run-in with timolol 0.5% bid, whereas in the Nixon
study, only 28% of the patients treated with BTFC, and
34% with DTFC were naive to treatment. Inclusion bias
due to known poor response to one or more of the
pharmacologic agents in BTFC or DTFC could have
affected the findings.
In this crossover trial, there were no serious adverse
events. Both DTFC and BTFC were generally well
tolerated by the study patients. The ocular side effects
were mild and similar for both fixed combinations,
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except for greater hyperaemia with BTFC, and greater
stinging and bitter taste with DTFC.
Unfortunately, to date, there is limited published
information evaluating the commonly used fixed
combinations vs monotherapies, or unfixed therapy,
beyond 2–3 time points in the daytime. It is important to
assess the therapeutic equivalence of fixed combinations
vs unfixed therapy, and between them throughout the
24-h period. This study compared for the first time the
24-h IOP efficacy with BTFC vs DTFC after a run-in
period of 2 months with timolol. In a comparative
efficacy study involving combined therapy with timolol,
it is important to include a run-in period with timolol to
exclude timolol non-responders, as well as those that
achieved adequate IOP control on timolol monotherapy.
The study’s crossover design may have facilitated the
determination of the real efficacy of the two fixed
combinations. The results herein may explain for the first
time why the 24-h IOP reduction provided by BTFC may
be less than might be anticipated. Considering the
previously documented 24-h efficacy of brimonidine and
BTFC,17,33,35 it is conceivable that the reason for the
reduced efficacy with BTFC may be the shorter duration
of action of brimonidine, when instilled twice daily,
whereas dorzolamide may have a longer duration of
action and better night-time efficacy.20,37
We observed the mean IOP, when six time-points over
24-h are averaged, to be significantly better with DTFC
than with BTFC. However, the 0.7 mm Hg difference over
24 h is small, and the longer-term significance of this
difference is uncertain. It must also be emphasised that
our results apply to POAG with mild-to-moderate
glaucoma and may not apply to other types of glaucoma.
This study did not investigate the long-term 24-hour
IOP-lowering efficacy of BTFC compared with DTFC.
Further research should elucidate the long-term 24-h
efficacy of these medications in glaucoma.
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